Brain damage in preterm newborns: biological response modification as a strategy to reduce disabilities.
Substances that promote the growth and maturation of oligodendrocytes and their precursors might protect against white matter injury. We suggest that neuroprotection can also be provided by such modulators of fetal and neonatal inflammatory responses as antiinflammatory cytokines, cytokine-binding proteins, and cytokine-receptor blockers. We briefly describe inflammatory responses in the fetus and newborn and show how they might contribute to brain damage. We conclude with the possibility that so-called biological response modifiers, which are drugs that modulate these inflammatory responses, might reduce the risk of brain damage and disabilities.
Dammann
O
O
Neuroepidemiology Unit, Department of Neurology, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Leviton
A
A
D001925:Brain Damage, Chronic / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000209:etiology; D019989:Persons with Intellectual Disabilities
D007155:Immunologic Factors